Is there clinical value in measuring suPAR levels in FSGS?
作者信息
Sever Sanja, Trachtman Howard, Wei Changli, Reiser Jochen
出版信息
Clin J Am Soc Nephrol. 2013 Aug;8(8):1273-5. doi: 10.2215/CJN.06170613. Epub 2013 Jul 25.
Abstract
摘要
相似文献
1
Is there clinical value in measuring suPAR levels in FSGS?测量局灶节段性肾小球硬化症患者的可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平有临床价值吗？
Clin J Am Soc Nephrol. 2013 Aug;8(8):1273-5. doi: 10.2215/CJN.06170613. Epub 2013 Jul 25.
2
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].[可溶性尿激酶受体血清水平在特发性与继发性局灶节段性肾小球硬化鉴别诊断中的价值]
Nefrologia. 2014;34(1):53-61. doi: 10.3265/Nefrologia.pre2013.Oct.12272.
3
Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.原发性及复发性局灶节段性肾小球硬化与血清可溶性尿激酶型纤溶酶原激活物受体水平密切相关。
Transplant Proc. 2015 Jul-Aug;47(6):1760-5. doi: 10.1016/j.transproceed.2015.03.048.
4
Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.局灶节段性肾小球硬化症中血清可溶性尿激酶型纤溶酶原激活物受体水平与类固醇反应性的关系
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1903-11. doi: 10.2215/CJN.02370314. Epub 2014 Oct 15.
5
Has the circulating permeability factor in primary FSGS been found?原发性 FSGS 中的循环通透因子是否已被发现？
Kidney Int. 2013 Aug;84(2):235-8. doi: 10.1038/ki.2013.204.
6
Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.可溶性尿激酶型纤溶酶原激活物受体（suPAR）在局灶节段性肾小球硬化症中的诊断和预后价值及其检测方法的影响。
Sci Rep. 2019 Sep 24;9(1):13783. doi: 10.1038/s41598-019-50405-8.
7
Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.血清可溶性尿激酶型纤溶酶原激活物受体与局灶节段性肾小球硬化症：系统评价和荟萃分析。
BMJ Open. 2019 Oct 7;9(10):e031812. doi: 10.1136/bmjopen-2019-031812.
8
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?目前的 ELISA 方法检测血清 suPAR 是否为 FSGS 的可靠诊断生物标志物？
Kidney Int. 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.
9
Glomerular disease: 'suPAR'-exciting times for FSGS.肾小球疾病：“可溶性尿激酶型纤溶酶原激活物受体”——局灶节段性肾小球硬化的激动人心时刻。
Nat Rev Nephrol. 2013 Mar;9(3):127-8. doi: 10.1038/nrneph.2013.15. Epub 2013 Feb 5.
10
Circulating factor in FSGS: a black sheep in the suPAR family?局灶节段性肾小球硬化中的循环因子：suPAR家族中的异类？
Pediatr Nephrol. 2013 Jul;28(7):1151-2. doi: 10.1007/s00467-013-2463-2. Epub 2013 Apr 10.
引用本文的文献
1
Podocyte-actin dynamics in health and disease.足细胞-肌动蛋白动态变化在健康与疾病中的表现。
Nat Rev Nephrol. 2016 Nov;12(11):692-710. doi: 10.1038/nrneph.2016.127. Epub 2016 Aug 30.
2
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.局灶节段性肾小球硬化中的可溶性尿激酶受体：科学观点综述
J Immunol Res. 2016;2016:2068691. doi: 10.1155/2016/2068691. Epub 2016 Jul 18.
3
Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.局灶节段性肾小球硬化症中血清可溶性尿激酶型纤溶酶原激活物受体水平与类固醇反应性的关系
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1903-11. doi: 10.2215/CJN.02370314. Epub 2014 Oct 15.
4
Permeability factors in focal and segmental glomerulosclerosis.局灶节段性肾小球硬化症中的通透性因素
Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21. doi: 10.1053/j.ackd.2014.05.010.
5
Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.血清可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平受微小病变型肾病综合征免疫抑制治疗的调节。
Pediatr Nephrol. 2014 Dec;29(12):2411-4. doi: 10.1007/s00467-014-2913-5. Epub 2014 Aug 17.
6
Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.血清可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平有助于区分儿童类固醇抵抗型与类固醇敏感型肾病综合征。
Pediatr Nephrol. 2015 Feb;30(2):301-7. doi: 10.1007/s00467-014-2892-6. Epub 2014 Jul 18.
7
The novel diagnostic biomarkers for focal segmental glomerulosclerosis.局灶节段性肾小球硬化的新型诊断生物标志物。
Int J Nephrol. 2014;2014:574261. doi: 10.1155/2014/574261. Epub 2014 Mar 26.
8
Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken.局灶节段性肾小球硬化中的可溶性尿激酶型纤溶酶原激活物受体：搅动而非震动
J Am Soc Nephrol. 2014 Aug;25(8):1611-3. doi: 10.1681/ASN.2014030257. Epub 2014 May 1.
9
Renal biopsy: use of biomarkers as a tool for the diagnosis of focal segmental glomerulosclerosis.肾活检：生物标志物作为诊断局灶节段性肾小球硬化症的工具的应用。
Dis Markers. 2014;2014:192836. doi: 10.1155/2014/192836. Epub 2014 Feb 25.
10
Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.肾小球滤过率降低是局灶节段性肾小球硬化症患者循环中可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平升高的主要因素。
Pediatr Nephrol. 2014 Sep;29(9):1553-60. doi: 10.1007/s00467-014-2808-5. Epub 2014 Apr 6.
本文引用的文献
1
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.利妥昔单抗是一种安全有效的长期治疗方案，可用于治疗依赖于皮质类固醇和钙调磷酸酶抑制剂的儿童特发性肾病综合征。
Kidney Int. 2013 Nov;84(5):1025-33. doi: 10.1038/ki.2013.211. Epub 2013 Jun 5.
2
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.尿而非血清可溶性尿激酶受体（suPAR）可识别肾移植候选者复发性 FSGS 病例。
Transplantation. 2013 Aug 27;96(4):394-9. doi: 10.1097/TP.0b013e3182977ab1.
3
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.血清可溶性尿激酶型纤溶酶原激活物受体水平与儿童特发性 FSGS：一项单中心报告。
Clin J Am Soc Nephrol. 2013 Aug;8(8):1304-11. doi: 10.2215/CJN.07680712. Epub 2013 Apr 25.
4
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.血浆可溶性尿激酶受体水平升高，但不能区分原发性和继发性局灶节段性肾小球硬化症。
Kidney Int. 2013 Aug;84(2):366-72. doi: 10.1038/ki.2013.55. Epub 2013 Feb 27.
5
Circulating suPAR in two cohorts of primary FSGS.原发性 FSGS 两队列的循环 suPAR。
J Am Soc Nephrol. 2012 Dec;23(12):2051-9. doi: 10.1681/ASN.2012030302. Epub 2012 Nov 8.
6
Focal segmental glomerulosclerosis.局灶节段性肾小球硬化症
N Engl J Med. 2011 Dec 22;365(25):2398-411. doi: 10.1056/NEJMra1106556.
7
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。
Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.
8
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.特发性肾病综合征和局灶节段性肾小球硬化症中的循环通透性因子。
Clin J Am Soc Nephrol. 2010 Nov;5(11):2115-21. doi: 10.2215/CJN.03800609. Epub 2010 Oct 21.
9
suPAR: the molecular crystal ball.可溶性尿激酶型纤溶酶原激活物受体：分子水晶球
Dis Markers. 2009;27(3):157-72. doi: 10.3233/DMA-2009-0657.
10
Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR.多功能受体的多种活性：裂解型和可溶性尿激酶型纤溶酶原激活物受体的作用
Front Biosci (Landmark Ed). 2009 Jan 1;14(7):2494-503. doi: 10.2741/3392.
Zotero 插件